Cytiva today unveiled its third Global Biopharma Index, revealing a decline in the global average score to 5.96, down from 6.08 in 2023 and 6.60 in 2021. This biannual survey, which encompasses insights from 1,250 biopharma executives across 22 countries, evaluates the ecosystem based on six critical pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy, and regulation. Notably, sustainability has been introduced as a new pillar for the 2025 survey.
The findings highlight a significant shift, with South Korea ascending to third place, reflecting its strategic investments in digital innovation and clinical trial capacity. Conversely, the United States has dropped from second to fifth place, primarily due to increasing regulatory uncertainties and policy disruptions. This trend indicates that economic strength is becoming less predictive of biopharma resilience, suggesting that countries focusing on advanced manufacturing and regulatory reform may gain a competitive edge.
As Michael May, CEO of the Centre for Commercialization of Regenerative Medicine, noted, the industry is transitioning from a global to a more regional focus, necessitating enhanced collaboration to bring sophisticated products to market. The report underscores the pressing need for the biopharma sector to address talent shortages, particularly in advanced drug modalities, while navigating a fragmented regulatory landscape that complicates capital raising efforts. Continued evolution and collaboration between government and industry are essential to meet the growing global demands for biopharmaceutical innovations.
Use the database as your supply chain compass →
